Pooled data from two other trials, comparing isosorbide mononitrate extended release tablets 60 mg once daily, isosorbide dinitrate 30 mg q.i.d., and placebo q.i.d. in patients with chronic stable angina using a randomized, double-blind, three-way crossover design found statistically significant increases in exercise tolerance times for isosorbide mononitrate extended release tablets compared to placebo at hours 4, 8, and 12 and to isosorbide dinitrate at hour 4. The increases in exercise tolerance on day 14, although statistically significant compared to placebo, were about half of that seen on day 1 of the trial.

Bookmark this page: